Human GH-release pharmacology
- Reported quantity
- 1–2 µg/kg intravenously
- Frequency
- Single administration per test
- Study duration
- Sampling over 120 minutes
2 µg/kg IV is the most repeated provocative figure in this literature.
Protocols · Growth Hormone
Hexarelin: literature-reported ranges
Hexarelin is the most potent of the classic hexapeptide secretagogues and, unusually, has a cardiac literature independent of its GH effects, mediated through CD36 rather than the ghrelin receptor.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- Synthetic hexapeptide GH secretagogue
- Reported half-life
- Approximately 55 minutes
- Routes used in the literature
- Subcutaneous, intravenous and intranasal in published studies
- Also written as
- —
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Repeated-administration desensitisation studies
- Reported quantity
- 1.5–2.0 µg/kg
- Frequency
- Twice daily
- Study duration
- 16 weeks in the longest published arm
GH response attenuated markedly over the study period — desensitisation is a documented finding, not a rumour.
Rodent cardioprotection models
- Reported quantity
- 50–100 µg/kg
- Frequency
- Once or twice daily
- Study duration
- 1–4 weeks
Cardiac effects in these models persist in GH-deficient animals, indicating a separate mechanism.
Mixed with 3 ml of bacteriostatic water
The same arithmetic for every vial size Hexarelin is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
Hexarelin · 3 ml bacteriostatic water
| Vial size | Concentration | Per 1 unit |
|---|---|---|
| 2 mg | 0.67 mg/ml | 7 mcg |
| 5 mg | 1.67 mg/ml | 17 mcg |
No single reported amount applies to this compound, so only the concentration and the value of one unit are shown. Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
A 5 mg vial in 2.5 mL of bacteriostatic water gives 2 mg/mL; 0.05 mL draws 100 µg.
Open the reconstitution calculatorHow to read these figures
- Cortisol and prolactin elevation is reported alongside GH — this is not a selective compound.
- Tachyphylaxis over weeks is one of the better-documented findings for the molecule.
- The cardiac literature uses quantities far above the GH-release figures.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
- [1]Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man
Ghigo E, Arvat E, Muccioli G, Camanni F. · Journal of Clinical Endocrinology & Metabolism / Eur J Endocrinol · 1994 · PMID 8126144
Twelve healthy young volunteers received hexarelin via intravenous (1-2 micrograms/kg), subcutaneous (1.5-3 micrograms/kg), intranasal (20 micrograms/kg), and oral (20-40 mg) routes to compare GH-releasing activity.
View the record - [2]Growth hormone-releasing activity of hexarelin in humans. A dose-response study
Imbimbo BP, Mant T, Edwards M, et al. · European Journal of Clinical Pharmacology · 1994 · PMID 7957536
Healthy volunteers received escalating doses of hexarelin to characterize the dose-response relationship for GH release in humans.
View the record - [3]Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study
Ghigo E, Arvat E, Rizzi G, et al. · Journal of Clinical Endocrinology & Metabolism · 1996 · DOI 10.1210/jcem.81.12.8954038
Healthy adult men received intravenous hexarelin doses ranging from 0 to 1.0 microgram/kg to study dose-dependent GH, cortisol, and prolactin release.
View the record
Search the databases yourself
Read the Hexarelin research briefOther growth hormone compounds
AOD-9604hGH fragment 176-191CJC-1295 (no DAC)Tetra-substituted GHRH (1-29) analogueCJC-1295 (no DAC) + IpamorelinGHRH analogue + selective ghrelin-receptor agonist blendCJC-1295 with DACGHRH analogue with albumin-binding drug affinity complex
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.